Janssen Pharma: Phase 3 Study of Ponesimod Met Primary, Most Secondary Endpoints
July 25 2019 - 5:20PM
Dow Jones News
By Stephen Nakrosis
The Janssen Pharmaceutical Companies of Johnson & Johnson
said Thursday that results from its Phase 3 Optimum study met
primary and most secondary endpoints.
The Optimum study evaluated the efficacy and safety of ponesimod
compared to Aubagio, or teriflunomide, in adult patients with
relapsing multiple sclerosis, the company said. The primary
endpoint of the Optimum study was annualized relapse rate up to the
end of the study, the company said.
Janssen said, "The safety profile observed for ponesimod in the
Optimum study was consistent with previous studies of
ponesimod."
The company said, "Data from the Optimum study will serve as the
basis of submissions to the U.S. Food and Drug Administration and
European Medicines Agency seeking approval of ponesimod as a
treatment for relapsing forms of multiple sclerosis, which are
anticipated for later this year."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
July 25, 2019 17:05 ET (21:05 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Apr 2023 to Apr 2024
